Catheter Precision, Inc. (NYSE American: VTAK) filed a 424B3 prospectus supplement registering 68,067,042 shares of common stock for potential resale by selling stockholders. The company had approximately 3,609,471 shares of common stock outstanding at the time of the filing, meaning the registered block represents roughly 25.3 times the existing share count.
If all registered shares were issued and sold, they would constitute approximately 96.2% of the resulting post-issuance float — a ratio that signals structurally significant dilution overhang for current holders of common stock.
Variable-Rate Conversion Mechanics
The shares stem largely from multiple series of preferred stock — Series C-1, C-2, C-3, and D — each carrying variable-rate conversion provisions. These preferred instruments convert into common stock at 80% of the lower of either the closing price or a five-day volume-weighted average price (VWAP), subject to a floor price of $0.35 per share. Critically, that floor is waivable, meaning under certain conditions conversions could occur at prices below it.
This type of structure is commonly referred to in capital-markets analysis as a "death-spiral" convertible. The defining characteristic is that the conversion price adjusts downward as the stock price declines, which can increase the number of shares issued upon conversion and, in turn, place additional pressure on the per-share metrics of the common stock.
The filing also reflects additional structural features including weighted-average anti-dilution protections for preferred holders, cashless exercise provisions, and reset mechanisms — all of which can further increase the effective share count under certain price scenarios.
Balance Sheet Context
At the time of the filing, Catheter Precision reported approximately $0.4 million in cash and an $18.5 million working capital deficit. These figures provide context for why the company has relied on variable-rate preferred equity as a financing mechanism: traditional capital-raising avenues may be constrained for issuers of this size and financial profile.
Float and Structural Implications
The scale of the registered share block relative to the current outstanding count is the central structural fact. Even partial conversion and resale of the preferred series would meaningfully expand the common share count. Because conversion prices float with the market — and specifically at a 20% discount to prevailing price benchmarks — each successive conversion has the mechanical effect of resetting the baseline for subsequent conversions.
The filing does not establish a fixed timeline for when or whether selling stockholders will convert their preferred holdings and resell the resulting common shares. However, the registration of all 68 million shares in a single prospectus supplement means the full block is eligible for public resale upon conversion without further SEC review.
Catheter Precision develops the VIVO system, a non-invasive cardiac mapping technology. The company's dilution profile under this filing stands out even among micro-cap issuers for the ratio of registered shares to existing float.